BACKGROUND According to relevant investigation and analysis,there are few research studies on the effect of excessive chemotherapy cycles after D2 gastrectomy on the survival of patients with gastric cancer.AIM To det...BACKGROUND According to relevant investigation and analysis,there are few research studies on the effect of excessive chemotherapy cycles after D2 gastrectomy on the survival of patients with gastric cancer.AIM To determine whether excessive chemotherapy cycles provide extra survival benefits,reduce recurrence rate,and improve survival rate in patients with stage Ⅱ or Ⅲ gastric cancer.METHODS We analyzed and summarized 412 patients with stage Ⅱ gastric cancer and 902 patients with stage Ⅲ gastric cancer who received D2 gastrectomy plus adjuvant chemotherapy or neoadjuvant chemotherapy.Analysis and comparison at a ratio of 1:1 is aimed at reducing realistic baseline differences(n=97 in each group of stage Ⅱ,n=242 in each group of stage Ⅲ).Progression-free survival,overall survival and recurrence were the main outcome indicators.RESULTS When the propensity score was matched,the baseline features of stage Ⅱ and Ⅲ gastric cancer patients were similar between the two groups.After a series of investigations,Kaplan-Meier found that the progression-free survival and overall survival of stage Ⅱ and Ⅲ gastric cancer patients were consistent between the two groups.The local metastasis rate(P=0.002),total recurrence rate(P<0.001)and distant metastasis rate(P=0.001)in the≥9 cycle group of stage Ⅲ gastric cancer were statistically lower than those in the<9 cycle group.The interaction analysis by Cox proportional hazard regression model showed that intestinal type,proximal gastrectomy,and≥6 cm maximum diameter of tumor had a higher risk of total mortality in the<9 cycles group.CONCLUSION Overall,≥9 chemotherapy cycles is not recommended for patients with stage Ⅱ and stage Ⅲ gastric cancer because it has an insignificant role in the prognosis of gastric cancer.However,for patients with stage Ⅲ gastric cancer,≥9 cycles of chemotherapy was shown to significantly decrease recurrence.展开更多
BACKGROUND Ubiquilins(UBQLNs)are important factors for cell proteostasis maintenance.UBQLNs are involved in the modulation of the cell cycle,as well as in apoptosis,membrane receptors regulation,DNA repair,epithelial-...BACKGROUND Ubiquilins(UBQLNs)are important factors for cell proteostasis maintenance.UBQLNs are involved in the modulation of the cell cycle,as well as in apoptosis,membrane receptors regulation,DNA repair,epithelial-mesenchymal transition,and mi RNA activities.They also affect the selection of double-strand break repair pathways.Abnormal UBQLNs expression can lead to many diseases,including cancer.Studies have found that the expression of Ubiquilin4(UBQLN4)is associated with the development of several tumor types.However,the association between UBQLN4 and cervical cancer has not been examined yet.AIM To investigate the expression of UBQLN4 in cervical cancer and to evaluate its correlation with disease prognosis.METHODS Immunohistochemistry was performed to examine the expression of UBQLN4 in 117 cervical cancer tissues and 32 matching pericervical tissues.Paired t-test(twotailed)was used to compare the differences between groups.We collected patients’clinical characteristics,including age,histological grade,pathologic type,lymph node metastasis,and FIGO stage(2018)and compared them by chi-square test.All patients were followed for 5.5 to 6.8 years.Kaplan-Meier method and logrank test were used to compare the differences in the overall survival(OS)and progression-free survival(PFS)among the different groups.RESULTS Overexpression of UBQLN4 was observed in 70.9%(83/117)of all cervical cancer tissues and in 15.6%(5/32)of the paired parauterine tissues.The expression of UBQLN4 was associated with lymph node metastasis,poor differentiation,and advanced stage,but the difference was not significant.Kaplan-Meier and log-rank test results suggested the high expression of UBQLN4 was associated with short OS and PFS.Regardless of UBQLN4 expression,the patient age and FIGO stage were also associated with disease prognosis.The statistically significant variables obtained from univariate the Kaplan-Meier analysis were subjected to Cox multivariate survival regression analysis,which showed that,in addition to the FIGO stage and age,UBQLN4 was also an independent prognostic marker for OS and PFS(P=0.011 and P=0.024,respectively).CONCLUSION The overexpression of UBQLN4 was associated with poor prognosis in cervical cancer.Our study proposed a novel prognostic factor and improved the existing understanding of the pathogenesis of cervical cancer.展开更多
Rituximab maintenance(RM)prolongs the progression-free survival(PFS)of responding patients with follicular lymphoma(FL),but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index(FLIP...Rituximab maintenance(RM)prolongs the progression-free survival(PFS)of responding patients with follicular lymphoma(FL),but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index(FLIPI)risk group is still confusing.We performed a retrospective analysis of the effect of RM treatments in patients with FL responding to induction therapy based on their FLIPI risk assessment carried out prior to treatment.We identified 93 patients between 2013 and 2019 who received RM every 3 months for≥4 doses(RM group),and 60 patients who did not accept RM or received rituximab less than 4 doses(control group).After a median follow-up of 39 months,neither median overall survival(OS)nor PFS was reached for the entire population.The PFS was significantly prolonged in the RM group compared to the control group(median PFS NA vs 83.1 months,P=.00027).When the population was divided into the 3 FLIPI risk groups,the PFS differed significantly(4-year PFS rates,97.5%vs 88.8%vs 72.3%,P=.01)according to group.There was no significant difference in PFS for FLIPI low-risk patients with RM compared to the control group(4-year PFS rates,100%vs 93.8%,P=.23).However,the PFS of the RM group was significantly prolonged for FLIPI intermediate-risk(4-year PFS rates,100%vs 70.3%,P=.00077)and high-risk patients(4-year PFS rates,86.7%vs 57.1%,P=.023).These data suggest that standard RM significantly prolongs the PFS of patients assigned to intermediate-and high-risk FLIPI groups but not to low-risk FLIPI group,and pending larger-scale studies to validate.展开更多
文摘BACKGROUND According to relevant investigation and analysis,there are few research studies on the effect of excessive chemotherapy cycles after D2 gastrectomy on the survival of patients with gastric cancer.AIM To determine whether excessive chemotherapy cycles provide extra survival benefits,reduce recurrence rate,and improve survival rate in patients with stage Ⅱ or Ⅲ gastric cancer.METHODS We analyzed and summarized 412 patients with stage Ⅱ gastric cancer and 902 patients with stage Ⅲ gastric cancer who received D2 gastrectomy plus adjuvant chemotherapy or neoadjuvant chemotherapy.Analysis and comparison at a ratio of 1:1 is aimed at reducing realistic baseline differences(n=97 in each group of stage Ⅱ,n=242 in each group of stage Ⅲ).Progression-free survival,overall survival and recurrence were the main outcome indicators.RESULTS When the propensity score was matched,the baseline features of stage Ⅱ and Ⅲ gastric cancer patients were similar between the two groups.After a series of investigations,Kaplan-Meier found that the progression-free survival and overall survival of stage Ⅱ and Ⅲ gastric cancer patients were consistent between the two groups.The local metastasis rate(P=0.002),total recurrence rate(P<0.001)and distant metastasis rate(P=0.001)in the≥9 cycle group of stage Ⅲ gastric cancer were statistically lower than those in the<9 cycle group.The interaction analysis by Cox proportional hazard regression model showed that intestinal type,proximal gastrectomy,and≥6 cm maximum diameter of tumor had a higher risk of total mortality in the<9 cycles group.CONCLUSION Overall,≥9 chemotherapy cycles is not recommended for patients with stage Ⅱ and stage Ⅲ gastric cancer because it has an insignificant role in the prognosis of gastric cancer.However,for patients with stage Ⅲ gastric cancer,≥9 cycles of chemotherapy was shown to significantly decrease recurrence.
文摘BACKGROUND Ubiquilins(UBQLNs)are important factors for cell proteostasis maintenance.UBQLNs are involved in the modulation of the cell cycle,as well as in apoptosis,membrane receptors regulation,DNA repair,epithelial-mesenchymal transition,and mi RNA activities.They also affect the selection of double-strand break repair pathways.Abnormal UBQLNs expression can lead to many diseases,including cancer.Studies have found that the expression of Ubiquilin4(UBQLN4)is associated with the development of several tumor types.However,the association between UBQLN4 and cervical cancer has not been examined yet.AIM To investigate the expression of UBQLN4 in cervical cancer and to evaluate its correlation with disease prognosis.METHODS Immunohistochemistry was performed to examine the expression of UBQLN4 in 117 cervical cancer tissues and 32 matching pericervical tissues.Paired t-test(twotailed)was used to compare the differences between groups.We collected patients’clinical characteristics,including age,histological grade,pathologic type,lymph node metastasis,and FIGO stage(2018)and compared them by chi-square test.All patients were followed for 5.5 to 6.8 years.Kaplan-Meier method and logrank test were used to compare the differences in the overall survival(OS)and progression-free survival(PFS)among the different groups.RESULTS Overexpression of UBQLN4 was observed in 70.9%(83/117)of all cervical cancer tissues and in 15.6%(5/32)of the paired parauterine tissues.The expression of UBQLN4 was associated with lymph node metastasis,poor differentiation,and advanced stage,but the difference was not significant.Kaplan-Meier and log-rank test results suggested the high expression of UBQLN4 was associated with short OS and PFS.Regardless of UBQLN4 expression,the patient age and FIGO stage were also associated with disease prognosis.The statistically significant variables obtained from univariate the Kaplan-Meier analysis were subjected to Cox multivariate survival regression analysis,which showed that,in addition to the FIGO stage and age,UBQLN4 was also an independent prognostic marker for OS and PFS(P=0.011 and P=0.024,respectively).CONCLUSION The overexpression of UBQLN4 was associated with poor prognosis in cervical cancer.Our study proposed a novel prognostic factor and improved the existing understanding of the pathogenesis of cervical cancer.
基金the National Natural Science Foundation of China(81970187,82170193,81920108006,and 81900203)Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2021-I2M-C&T-B-081).
文摘Rituximab maintenance(RM)prolongs the progression-free survival(PFS)of responding patients with follicular lymphoma(FL),but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index(FLIPI)risk group is still confusing.We performed a retrospective analysis of the effect of RM treatments in patients with FL responding to induction therapy based on their FLIPI risk assessment carried out prior to treatment.We identified 93 patients between 2013 and 2019 who received RM every 3 months for≥4 doses(RM group),and 60 patients who did not accept RM or received rituximab less than 4 doses(control group).After a median follow-up of 39 months,neither median overall survival(OS)nor PFS was reached for the entire population.The PFS was significantly prolonged in the RM group compared to the control group(median PFS NA vs 83.1 months,P=.00027).When the population was divided into the 3 FLIPI risk groups,the PFS differed significantly(4-year PFS rates,97.5%vs 88.8%vs 72.3%,P=.01)according to group.There was no significant difference in PFS for FLIPI low-risk patients with RM compared to the control group(4-year PFS rates,100%vs 93.8%,P=.23).However,the PFS of the RM group was significantly prolonged for FLIPI intermediate-risk(4-year PFS rates,100%vs 70.3%,P=.00077)and high-risk patients(4-year PFS rates,86.7%vs 57.1%,P=.023).These data suggest that standard RM significantly prolongs the PFS of patients assigned to intermediate-and high-risk FLIPI groups but not to low-risk FLIPI group,and pending larger-scale studies to validate.
